Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective.
Advanced stage
Optimization of treatment
Ovarian cancer
Peritoneal carcinomatosis
Quality of care
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
29
06
2018
accepted:
13
10
2018
pubmed:
1
11
2018
medline:
28
11
2019
entrez:
1
11
2018
Statut:
ppublish
Résumé
Optimal upfront treatment of patients with advanced ovarian cancer is complex and requires the adequate function of a multidisciplinary team. Specific standard of quality of care needs to be taken into consideration. A literature search in PubMed was performed using the following criteria: ("ovarian neoplasms"[MeSH Terms] OR ("ovarian"[All Fields] AND "neoplasms"[All Fields]) OR "ovarian neoplasms"[All Fields] OR ("ovarian"[All Fields] AND "cancer"[All Fields]) OR "ovarian cancer"[All Fields])"[Date - Publication]: "2018/01/14"[Date - Publication]). This article describes how to optimize the surgical management of advanced ovarian cancer, to achieve the best results in terms of survival and quality of life. For this purpose, this document will cover aspects related to pre-, intra- and postoperative care of newly diagnosed advanced ovarian cancer patients. Optimizing upfront treatment of patients with advanced ovarian cancer is complex and requires a structured quality management program including the wise judgment of a multidisciplinary team. Surgeries performed by gynecologic oncologists with formal training in cytoreductive techniques at referral centers are crucial factors to obtain better clinical and oncological outcomes. However, other factors such as the patient's clinical status, the hospital infrastructure and equipment, as well as the tumor biology of each individual patient should also be taken into account before deciding on an initial therapeutic strategy for advanced-stage ovarian cancer to offer patients the best quality of care.
Sections du résumé
BACKGROUND
BACKGROUND
Optimal upfront treatment of patients with advanced ovarian cancer is complex and requires the adequate function of a multidisciplinary team. Specific standard of quality of care needs to be taken into consideration.
METHODS
METHODS
A literature search in PubMed was performed using the following criteria: ("ovarian neoplasms"[MeSH Terms] OR ("ovarian"[All Fields] AND "neoplasms"[All Fields]) OR "ovarian neoplasms"[All Fields] OR ("ovarian"[All Fields] AND "cancer"[All Fields]) OR "ovarian cancer"[All Fields])"[Date - Publication]: "2018/01/14"[Date - Publication]).
RESULTS
RESULTS
This article describes how to optimize the surgical management of advanced ovarian cancer, to achieve the best results in terms of survival and quality of life. For this purpose, this document will cover aspects related to pre-, intra- and postoperative care of newly diagnosed advanced ovarian cancer patients.
CONCLUSION
CONCLUSIONS
Optimizing upfront treatment of patients with advanced ovarian cancer is complex and requires a structured quality management program including the wise judgment of a multidisciplinary team. Surgeries performed by gynecologic oncologists with formal training in cytoreductive techniques at referral centers are crucial factors to obtain better clinical and oncological outcomes. However, other factors such as the patient's clinical status, the hospital infrastructure and equipment, as well as the tumor biology of each individual patient should also be taken into account before deciding on an initial therapeutic strategy for advanced-stage ovarian cancer to offer patients the best quality of care.
Identifiants
pubmed: 30377941
doi: 10.1007/s12094-018-1967-4
pii: 10.1007/s12094-018-1967-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
656-664Références
Obstet Gynecol. 2003 Sep;102(3):499-505
pubmed: 12962932
Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4
pubmed: 15904446
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:35-40
pubmed: 16515565
Cancer. 2007 Apr 15;109(8):1513-22
pubmed: 17354232
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
J Clin Oncol. 2007 Nov 1;25(31):4946-51
pubmed: 17971592
J Natl Cancer Inst. 2008 Mar 19;100(6):399-406
pubmed: 18334710
Gynecol Oncol. 2009 Feb;112(2):422-36
pubmed: 18990435
Eur J Cancer. 2009 Mar;45(4):517-26
pubmed: 19013789
Gynecol Oncol. 2009 Apr;113(1):68-74
pubmed: 19176236
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Int J Gynecol Cancer. 2009 Jan;19(1):94-102
pubmed: 19258949
Int J Gynecol Cancer. 2009 Jan;19(1):124-8
pubmed: 19258953
Br J Cancer. 2009 Oct 6;101(7):1066-73
pubmed: 19738608
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Gynecol Oncol. 2010 Oct;119(1):38-42
pubmed: 20609464
Gynecol Oncol. 2011 Jan;120(1):23-8
pubmed: 20933255
Obstet Gynecol. 2011 Sep;118(3):537-47
pubmed: 21860281
Dan Med Bull. 2011 Nov;58(11):A4331
pubmed: 22047929
Int J Gynecol Cancer. 2012 Feb;22(2):226-31
pubmed: 22080889
Ann Surg Oncol. 2012 May;19(5):1394-1401
pubmed: 22302265
AJR Am J Roentgenol. 2012 Jun;198(6):1453-9
pubmed: 22623562
Gynecol Oncol. 2013 Jan;128(1):6-11
pubmed: 23006973
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Eur Radiol. 2013 Sep;23(9):2636-42
pubmed: 23604800
Am J Obstet Gynecol. 2013 Nov;209(5):462.e1-462.e11
pubmed: 23891632
Eur Radiol. 2014 Apr;24(4):889-901
pubmed: 24322510
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
Gynecol Oncol. 2014 Jul;134(1):60-7
pubmed: 24680770
BJOG. 2015 May;122(6):843-9
pubmed: 25132394
Oncology. 2014;87(5):293-9
pubmed: 25139548
Int J Gynecol Cancer. 2015 Mar;25(3):407-15
pubmed: 25695545
Obstet Gynecol. 2015 Apr;125(4):833-42
pubmed: 25751200
Gynecol Oncol. 2015 Sep;138(3):554-9
pubmed: 26093061
Curr Oncol. 2015 Aug;22(4):e282-93
pubmed: 26300679
Gynecol Oncol. 2016 Feb;140(2):313-22
pubmed: 26603969
Gynecol Oncol. 2016 Feb;140(2):323-32
pubmed: 26757238
Int J Gynecol Cancer. 2016 May;26(4):801-6
pubmed: 26937753
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
Gynecol Oncol. 2016 Jun;141(3):524-530
pubmed: 27090157
Gynecol Oncol. 2016 Aug;142(2):211-6
pubmed: 27238084
Int J Gynecol Cancer. 2016 Sep;26(7):1354-63
pubmed: 27648648
Gynecol Oncol. 2016 Oct;143(1):3-15
pubmed: 27650684
J Clin Oncol. 2017 Feb 20;35(6):613-621
pubmed: 28029317
World J Nucl Med. 2017 Jul-Sep;16(3):176-185
pubmed: 28670174